The Drug Enforcement Administration has issued a final order that, effective May 16, will place the substance AH-7921 (3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, into schedule I of the Controlled Substances Act. The DEA states that AH-7921 is a μ-opioid receptor agonist with analgesic activity similar to that of morphine but that it has no currently accepted medical use in treatment in the U.S.
This action imposes the regulatory controls and administrative, civil and criminal sanctions applicable to schedule I controlled substances on persons who handle (import, export, manufacture, distribute, engage in research or conduct instructional activities with) this substance. Among other things, any person who handles or desires to handle AH-7921 must be registered with the DEA to conduct such activities, and any person who does not desire or is not able to obtain a registration must surrender all quantities of currently held AH-7921 or may transfer all quantities to a registered person. In addition, all importation and exportation of AH-7921 must be in compliance with 21 USC 952, 953, 957 and 958 and in accordance with 21 CFR part 1312.